Plant thymidine kinase 1: a novel efficient suicide gene for malignant glioma therapy
Open Access
- 13 February 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (6) , 549-558
Abstract
The prognosis for malignant gliomas remains poor, and new treatments are urgently needed. Targeted suicide gene therapy exploits the enzymatic conversion of a prodrug, such as a nucleoside analog, into a cytotoxic compound. Although this therapeutic strategy has been considered a promising regimen for central nervous system (CNS) tumors, several obstacles have been encountered such as inefficient gene transfer to the tumor cells, limited prodrug penetration into the CNS, and inefficient enzymatic activity of the suicide gene. We report here the cloning and successful application of a novel thymidine kinase 1 (TK1) from the tomato plant, with favorable characteristics in vitro and in vivo. This enzyme (toTK1) is highly specific for the nucleoside analog prodrug zidovudine (azidothymidine, AZT), which is known to penetrate the blood-brain barrier. An important feature of toTK1 is that it efficiently phosphorylates its substrate AZT not only to AZT monophosphate, but also to AZT diphosphate, with excellent kinetics. The efficiency of the toTK1/AZT system was confirmed when toTK1-transduced human glioblastoma (GBM) cells displayed a 500-fold increased sensitivity to AZT compared with wild-type cells. In addition, when neural progenitor cells were used as delivery vectors for toTK1 in intracranial GBM xenografts in nude rats, substantial attenuation of tumor growth was achieved in animals exposed to AZT, and survival of the animals was significantly improved compared with controls. The novel toTK1/AZT suicide gene therapy system in combination with stem cell–mediated gene delivery promises new treatment of malignant gliomas.Keywords
This publication has 36 references indexed in Scilit:
- Gene therapy: can neural stem cells deliver?Nature Reviews Neuroscience, 2006
- Deoxyribonucleoside kinases: two enzyme families catalyze the same reactionTrends in Biochemical Sciences, 2005
- Introduction to the Background, Principles, and State of the Art in Suicide Gene TherapyMolecular Biotechnology, 2005
- Gene therapy of experimental brain tumors using neural progenitor cellsNature Medicine, 2000
- Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinaseCancer Gene Therapy, 2000
- Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humansGene Therapy, 1999
- Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cellsNature Medicine, 1997
- Absorption and Elimination Kinetics of Zidovudine in the Cerebrospinal Fluid in HIV-1-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Immune system in suicide-gene therapyThe Lancet, 1997
- Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.Proceedings of the National Academy of Sciences, 1996